EC conducts surprise antitrust inspections
The EC has been knocking on the doors of pharmaceutical companies to conduct surprise inspections; the agency will be looking specifically for signs of anticompetitive behaviour.
The EC has been knocking on the doors of pharmaceutical companies to conduct surprise inspections; the agency will be looking specifically for signs of anticompetitive behaviour. A memo released by the EC said: "The EC has reason to believe that the provisions of the EC Treaty prohibiting restrictive business practices and/or abuse of a dominant market position (Articles 81 and 82) may have been infringed."
The EC has been watching the pharma industry for signs of anticompetitive behaviour for more than a year. In January 2008, the EC launched a sector enquiry after a significant decline in FDA drug approvals; in particular there was concern that large pharma companies were blocking market entry of generic products. This fear was confirmed in a final report released in July 2009. In response, the EC said it would intensify its scrutiny of the pharma sector and monitor settlements between originator and generic drug companies.
The latest inspections, which were conducted on 6 October, are the first step in the investigations and the EC has stressed that such inspections do "not mean that the companies are guilty".
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
